PPA1, TRIM68 and FBXO46: Potential Therapeutic Targets for Triple Negative Breast Cancer

Area of Science:

• Oncology
• Biochemistry
• Molecular Biology

Background:

• Triple-negative breast cancer (TNBC) is an aggressive subtype with high recurrence rates.
• Novel therapeutic strategies and biomarkers are critical for improving TNBC patient outcomes.

Purpose of the Study:

• To investigate the therapeutic potential of ML364 in TNBC.
• To identify potential prognostic biomarkers associated with the USP2-mediated pathway in TNBC.

Main Methods:

• Cell cytotoxicity assays were performed to evaluate ML364 efficacy.
• Proteomic analysis (2DE, LC-MS/MS) and gene expression analysis (RT-qPCR) identified differentially expressed proteins and genes.
• Bioinformatic databases (TIMER, HPA, UALCAN) were used for further validation.

Main Results:

• ML364 treatment induced cytotoxicity in TNBC cells.
• Proteins PPA1, TRIM68, and FBXO46 were identified as differentially expressed and linked to the USP2-mediated pathway.
• These proteins showed higher expression in primary tumors compared to normal tissues and were downregulated by ML364.

Conclusions:

• The study elucidates the USP2-mediated signaling pathway's role in TNBC.
• PPA1, TRIM68, and FBXO46 are potential prognostic biomarkers for TNBC.
• ML364 demonstrates potential as a therapeutic candidate for TNBC by targeting the USP2 pathway.